Pro-apoptotic properties of hyperforin in leukemic cells from patients with B-cell chronic lymphocytic leukemia

被引:0
|
作者
C Quiney
C Billard
A M Faussat
C Salanoubat
A Ensaf
Y Naït-Si
J D Fourneron
J-P Kolb
机构
[1] UMR 736 INSERM/Université Paris VI,
[2] Centre de Recherches Biomédicales des Cordeliers,undefined
[3] Laboratory of Galenic and Industrial Pharmacy,undefined
[4] Faculty of Pharmacy,undefined
来源
Leukemia | 2006年 / 20卷
关键词
hyperforin; B-CLL; apoptosis; nitric oxide; p27;
D O I
暂无
中图分类号
学科分类号
摘要
The effects of the hyperforin (HF), a natural phloroglucinol purified from Hypericum perforatum, were investigated ex vivo on leukemic cells from patients with B-cell chronic lymphocytic leukemia (B-CLL). HF was found to promote apoptosis of B-CLL cells, as shown by time- and dose-dependent stimulation of phosphatidylserine externalization and DNA fragmentation, by disruption of the mitochondrial transmembrane potential, caspase-3 activation and cleavage of the caspase substrate PARP-1. Moreover, HF-induced downregulation of Bcl-2 and Mcl-1, two antiapoptotic proteins that control mitochondrial permeability. HF also downregulated two proteins which are overexpressed by B-CLL patients' cells, the cell cycle inhibitor p27kip1 through caspase-dependent cleavage into a p23 form, and the nitric oxid (NO) synthase of type 2 (inducible NO synthase). This latter was accompanied by reduction in the production of NO known to be antiapoptotic in B-CLL cells. Preventing effects of the general caspase inhibitor z-VAD-fmk indicated that HF-promoted apoptosis of B-CLL cells was mostly caspase dependent. Furthermore, normal B lymphocytes purified from healthy donors appeared less sensitive to HF-induced apoptosis than B-CLL cells. These results indicate that HF may be of interest in the development of new therapies for B-CLL based on the induction of apoptosis and combination with cell cycle-dependent antitumor drugs.
引用
收藏
页码:491 / 497
页数:6
相关论文
共 50 条
  • [31] Apoptotic effect of fludarabine is independent of expression of IAPs in B-cell chronic lymphocytic leukemia
    Silva, KL
    Vasconcellos, DV
    Castro, EDD
    Coelho, AM
    Linden, R
    Maia, RC
    APOPTOSIS, 2006, 11 (02) : 277 - 285
  • [32] Chronic lymphocytic leukemia: revelations from the B-cell receptor
    Stevenson, FK
    Caligaris-Cappio, F
    BLOOD, 2004, 103 (12) : 4389 - 4395
  • [33] Alemtuzumab for B-cell chronic lymphocytic leukemia
    Robak, Tadeusz
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (07) : 1033 - 1051
  • [34] Rituximab in B-cell chronic lymphocytic leukemia
    Lin, TS
    Lucas, MS
    Byrd, JC
    SEMINARS IN ONCOLOGY, 2003, 30 (04) : 483 - 492
  • [35] Alemtuzumab in B-cell chronic lymphocytic leukemia
    Shapira, I
    Grossbard, ML
    CLINICAL LYMPHOMA, 2004, 4 (04): : 228 - 229
  • [36] Histopathology of B-cell chronic lymphocytic leukemia
    Pileri, SA
    Sabattini, E
    Agostinelli, C
    Bodega, L
    Rossi, M
    Zinzani, PL
    Marafioti, T
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2004, 18 (04) : 807 - +
  • [37] Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia
    C Campàs
    M Dalmau
    B Montaner
    M Barragán
    B Bellosillo
    D Colomer
    G Pons
    R Pérez-Tomás
    J Gil
    Leukemia, 2003, 17 : 746 - 750
  • [38] The origin of B-cell chronic lymphocytic leukemia
    Ghia, P
    Caligaris-Cappio, F
    SEMINARS IN ONCOLOGY, 2006, 33 (02) : 150 - 156
  • [39] Prodigiosin induces apoptosis of B and T cells from B-cell chronic lymphocytic leukemia
    Campàs, C
    Dalmau, M
    Montaner, B
    Barragán, M
    Bellosillo, B
    Colomer, D
    Pons, G
    Pérez-Tomás, R
    Gil, J
    LEUKEMIA, 2003, 17 (04) : 746 - 750
  • [40] PROLIFERATION OF LEUKEMIC LYMPHOCYTES-B FROM CHRONIC LYMPHOCYTIC-LEUKEMIA BY B-CELL GROWTH-FACTOR
    SCOUROS, MA
    BOHLEBERMATZA, M
    MEHTA, S
    MAIZEL, A
    FEDERATION PROCEEDINGS, 1983, 42 (04) : 839 - 839